Hepatitis viruses in Ethiopia: a systematic review and meta-analysis by unknown
RESEARCH ARTICLE Open Access
Hepatitis viruses in Ethiopia: a systematic
review and meta-analysis
Yeshambel Belyhun1,2*, Melanie Maier1, Andargachew Mulu1,2, Ermias Diro3 and Uwe Gerd Liebert1
Abstract
Background: The existing seroepidemiological data on viral hepatitis in Ethiopia showed a wide variation in
prevalence pattern and the clinical and public health burden have been underestimated. The aim of this systematic
review and meta-analysis was to provide a clear and comprehensive estimation of viral hepatitis epidemiology and
the potential clinical burdens in Ethiopia.
Methods: A comprehensive literature search was carried out from five decades (1968–2015) published studies from
biomedical databases; PubMed, Google scholar, Medline and Web of Science.
Results: The overall pooled prevalence of hepatitis B virus (HBV) was 7.4% (95%CI: 6.5–8.4). The pooled prevalence
among subgroups showed 5.2% (95%CI: 3.7–7.4) in human immunodeficiency virus (HIV) infected individuals, 8.0%
(95%CI: 5.9–10.7) in community based studies, 8.4% (95%CI: 5.4–12.7) in blood donors, 11.0% (95%CI: 7.5–15.9) in
immigrants and 6.9% (95%CI: 5.6–8.5) in other groups. Among study parameters considered during meta-regression
analysis, only study years were associated with a decreasing HBV prevalence rate over time. The overall pooled
prevalence of anti-hepatitis C virus antibody (anti-HCV) was 3.1% (95%CI: 2.2–4.4). Unlike HBV, the anti-HCV
prevalence in HIV infected individuals was higher (5.5%, 95%CI: 3.8–7.8%, p = 0.01) than the prevalence observed in
the other subgroup of study population. Although relatively few data were available, hepatitis virus A (HAV), D
(HDV) and E (HEV) were also circulated in Ethiopia.
Conclusions: This review indicates that all types of viral hepatitis origins are endemic in Ethiopia. Adapting a
recommended diagnostic and treatment algorithm of viral hepatitis in the routine healthcare systems and
implementing prevention and control policies in the general population needs an urgent attention.
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Background
Hepatitis viruses, such as HAV, HBV, HCV, HDV and
HEV cause potentially life-threatening inflammation of
the liver, which is characterized by acute and chronic
forms of liver disease. According to 2013 World Health
Organization (WHO) global health impact report of viral
hepatitis [1], more than 240 and 150 million populations
were affected by chronic liver disease due to HBV and
HCV, respectively. Africa has the second largest number
of chronic HBV carriers after Asia and is considered as a
region of high endemicity [2]. Despite its high
prevalence and highly infectious nature, HCV remains
under-diagnosed and under-reported in most African
countries [1]. Regarding HAV, Africa is known by high
prevalence rate and nearly all older children and adults
in the region acquired anti-HAV antibody immunity [3].
HEV is also one of the leading causes of major outbreaks
of acute viral hepatitis worldwide, especially in develop-
ing countries [4]. Similarly, HDV is prevalent worldwide
and associated with the most severe form of viral
hepatitis [5].
In Ethiopia, an old clinical study showed that liver dis-
ease accounted for 12% hospital admissions and 31%
hospital mortality [6]. Moreover, in Ethiopia and neigh-
bouring Kenya more than 60% of chronic liver disease
and up to 80% of hepatocellular carcinoma (HCC) are
due to chronic HBV and HCV infections [6, 7]. Unlike
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HAV, HDV and HEV, which are not extensively studied,
several HBV and HCV seroepidemiological studies were
available in the country. However, the majority of the re-
ports showed epidemiological variations of 2.1 to 25.0%
over time and across geographical areas as well as the
same localities [8–17]. More importantly, because of
HIV pandemic and possible epidemiological overlap as
the result of shared transmission ways and risk factors,
viral hepatitis-HIV co-infection and subsequent severe
forms of clinical complications could be potentially high
in the country. Nevertheless, the clinical and public
health burdens due to viral hepatitis in general are still
given no emphasis in the country’s health system. For in-
stance, a recent report showed the presence of very lim-
ited knowledge, minimal awareness and underestimation
of the viral hepatitis prevalence and disease burden in
the country, which have resulted insufficient budgetary
and organizational focus [7]. Moreover, according to the
WHO report, Ethiopia is regarded as a country with no
national strategy for surveillance, prevention and control
of viral hepatitis, but the country is classified under the
geographical regions with intermediate to hyperendemic
viral hepatitis infections [1]. Thus, the lack of a consoli-
dated epidemiological data on the burden of viral hepa-
titis in Ethiopia might be responsible for the absence of
practical action at the policy level. Therefore, this sys-
tematic review and meta-analysis was made using data
published in the last five decades (1968–2015) to provide
a quantified estimate of the problem as a step toward for
a better understanding of the viral hepatitis epidemi-
ology, clinical burden and the situation of human im-
munodeficiency virus (HIV) co-infection in Ethiopia.
Methods
Search strategy
A comprehensive literature search was carried out from
biomedical databases; PubMed, Google scholar, Medline
and Web of Science according to Operations Manual of
the Global Burden of Diseases for systematic epidemio-
logical reviews of targeted diseases or condition frequency
[18] and Preferred Reporting Items for Systematic Reviews
and Meta-analysis (PRISMA) [19]. The search focused on
all published studies with epidemiological and/or clinical
data on the seroprevalence of hepatitis viruses (HAV,
HBV, HCV, HDV, and HEV) in Ethiopia from the first sci-
entific description (1968) to 2015. During the search, the
following keywords (terms) were used; [“hepatitis A” AND
(seroprevalence OR prevalence) AND “Ethiopia”], [“hepa-
titis B” AND (seroprevalence OR prevalence) AND
“Ethiopia”], [“hepatitis C” AND (seroprevalence OR preva-
lence) AND “Ethiopia”], [“hepatitis D” AND (seropreva-
lence OR prevalence) AND “Ethiopia”], [“hepatitis E”
AND (seroprevalence OR prevalence) AND “Ethiopia”].
The search was repeated by replacing the full written
phrases using the abbreviated form of each respective
hepatitis virus. Similarly, key terms like “Epidemiology”,
“Viral liver disease”, “Viral hepatitis and HIV co-
infections” were used in place of the terms “Seropreva-
lence” and “Prevalence”.
Inclusion and exclusion criteria
Abstracts were screened to determine the relevance of
each study. All studies that reported “seroprevalence”
and/or “clinical isolation of viral hepatitis” were selected
for inclusion according to PRISMA Flow Diagram [19]
(Fig. 1). The inclusion was restricted to original research
articles published in English language. The studies also
included Ethiopian Jews who immigrated to Israel and
screened for hepatitis viruses at the time of their arrival.
Data source
The screened articles were organized and subgrouped
into five major study population types: community
based, blood donors, symptomatic liver disease patients,
HIV co-infected individuals and various other groups
(healthcare workers and medical waste handlers, out and
inpatient department patients, street dwellers, pregnant
women, diabetic patients, HIV voluntary counselling and
testing (VCT) centres clients and commercial sex
workers).
Data extraction and quality assessment
In each abstract and/or full text of the article which was
considered to be eligible, information about the study
area, year of sample collection and publication, study
population, sample size, type of screening kits used and
other useful variables were recorded (Additional files 1
and 2). The studies were assessed to identify ‘seropreva-
lence’ as an outcome of serological evidence for each of
the hepatitis viruses. The quality and eligibility of the
screened articles were assessed using a 12 point scoring
system based on modified Downs and Black [20] check
lists. Special emphases were given for clarity of objective,
method, study population characteristics and finding
presentations. Articles with low quality score were ex-
cluded during the meta-analysis (Additional files 1 and 2).
Data analysis
The extracted data were systematically restructured
among viral origin, study area, study groups and study
year during the systematic review. The subgrouped data
were analysed using simple descriptive statistics during
the systematic review. Accordingly, a median and inter
quartile range (IQR) values across each subgroup (com-
munity based, blood donors, symptomatic liver disease
patients, HIV infected individuals, and various other
groups of the society were calculated because of
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expected heterogeneity in terms of the study area, time,
sample size and the study design.
During the meta-analysis, all selected studies were com-
bined and a random effects model by DerSimonian and
Laird [21] were used to estimate overall pooled prevalence.
Since the risks of viral hepatitis exposure are potentially
high in symptomatic liver disease patients, the meta-
analysis was done independently in order to avoid the
potential bias on the outcome of pooled estimation. Coh-
ran’s Q (low P value indicates presence of heterogeneity)
and and I squared (I2) (with I2 > 50% denoting substantial
heterogeneity statistical tests) were conducted to test het-
erogeneity [22]. The subgroup analysis was performed
among the community based studies, blood donors, HIV
infected individuals and other groups. The subgroup ana-
lysis was not considered for the screening kits used because
of the observed homogeneity in the types of the kits (which
include an immunoassay based screening kits such as en-
zyme linked immunoassay, radioimmunoassay and chro-
matographic immunoassay) (Additional files 1 and 2).
Meta-regression analysis was used to determine potential
confounders such as mean age groups, study population
types, year of study and geographical zones. The mean age
group meta-regression was considered for those studies
which only reported the mean age (Additional files 1 and
2). The overall fixed and random effects model with 95%
confidence intervals (95% CIs) were calculated and illus-
trated using a forest plot graph presentation. The meta-
analysis was not considered for data extracted for HAV,
HDV and HEV since the number of available studies was
very small. Compressive meta-analysis software version 3.3.,
2014 (www.meta-analysis.com) was used during the meta-
analysis.
Results
Demographic and study population characteristics
The population of Ethiopia was 22 million at the time
(1960s) when the first HBV seroprevalence data were re-
ported. After 30 years, when many of the seroepidemiologi-
cal and few clinical reports of hepatitis viruses were
available, the population steadily increased to 48 million
[23]. Currently, with a population of 94 million, the country
is the second most populous in Africa. The total study
population size screened for hepatitis viruses and involved
in this systematic review and meta-analysis were 79,931.
Among these, 62,955 were screened for hepatitis viruses
from the general population. About 5,229 were from symp-
tomatic patients with acute (867) and chronic (1020) liver
diseases, and outpatient department attendants (3,342).
The rest 11,747 were from HIV infected individuals.
Geographically, the majority of population screened for
hepatitis viruses were from central Ethiopia (mainly in
Addis Ababa) (45,037), northern Ethiopia (16,071), south-
ern Ethiopia (17, 207) and from Ethiopian immigrants to
Israel (1616). Overall, 68 studies were eligible for the review
and among these, 26 studies reported both HBV and anti-
Fig. 1 Flow diagram of studies reviewed, screened and included
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HCV seroprevalence and the rest 6 and 36 studies reported
only HCV and HBV, respectively. The mean age group of
the study population screened for HBV and HCV was 28.9
± 6.1 (range 14–48) and 28.2 ± 7.3 (range 16–55) years old,
respectively. The peak prevalence was reported between
the group of 24–39 and 20–37 years old, respectively to
HBV and HCV (Additional files 1 and 2). All of the selected
studies were used immunoassay based kits of various types
as their primary screening test. In addition, only four (6.1%)
studies (two each for HBV and HCV) used PCR for meas-
uring viraemia level (Additional files 1 and 2).
Epidemiology of HBV
The first documented HBsAg prevalence rate was 3.9% in
1968 [24]. Then later the magnitude of the peak HBsAg
prevalence (10.8%) was available in 1986 and 1989 [25, 26]
and then decreased to 6.2% in 2003 [27] and 5.3% in 2007
[28] from the community based studies (Fig. 2a). However,
studies conducted in blood donors (Fig. 2b) reported a
slightly higher median prevalence of 8.7% (IQR= 4.6–16.9)
than the 6.2% median (IQR = 5.6–9.9) prevalence rate in the
community based studies (Fig. 2a). Moreover, the reports
from the blood donors of the same localities like in Bahir
Dar (25 vs. 4.11%) [8, 13], Jimma (24.2 vs. 2.1%) [14, 15]
and Gondar (14.4 vs. 4.7%) [16, 17] showed marked
epidemiological discrepancies over time (Fig. 2b). The
HBsAg was also reported among various segments of the
society such as healthcare professionals (7.3–9.0%) [29, 30],
medical waste handlers (6.0–6.3%) [31, 32], outpatient and
inpatient department attendants (4.7–7.4%) [33, 34], street
dwellers (10.9%) [35], pregnant women (3.0–7.3%) [36–40],
diabetic patients (3.7%) [41], HIV VCT centres clients
(5.7%) [10, 42] and commercial sex workers (6.0%)
[43] (Fig. 2c). The HBsAg prevalence among Ethio-
pians Jews who immigrated to Israel in different times
also showed 6.2 to 19% prevalence rate (11.5% me-
dian; IQR 7.6–16.6) (Fig. 2d). Overall, the median
HBsAg prevalence in the general population (Fig. 2a-d)
showed 6.3% (IQR = 5.2–10.8) over the last five decades.
Fourty two (67.7%) out of the 62 studies which reported
HBsAg prevalence (Additional file 1) were used in the
meta-analysis among the general population. The Cohran’s
Q and I2 statistic for HBsAg was 509.7 and 91.9%
(p < 0.001), respectively which showed the studies were het-
erogeneous. The overall pooled prevalence of HBV was
7.4% (95%CI: 6.5–8.4) (Fig. 3). The subgroup meta-analysis
of study parameters such as the mean age group, study
population types, year of study and geographical zones
showed significant variations in the HBV prevalence
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Fig. 2 HBsAg prevalence among the community based studies (a) [24–26, 52, 59, 76, 85, 87, 88], blood donors (b) [8, 9, 13–17, 57, 89, 90], various
groups of the society (healthcare workers, outpatient department attendants, medical waste handlers, pregnant women, HIV voluntary counseling
and testing (VCT) clients, commercial sex workers) (c) [10, 29–41] and Ethiopian Jews immigrants to Israel (d) [54, 91–96]
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subgroup was 5.2% (95%CI: 3.7–7.4) in HIV infected indi-
viduals, 8.0% (95%CI: 5.9–10.7) in community based stud-
ies, 8.4% (95%CI: 5.4–12.7) in blood donors, 11.0% (95%CI:
7.5–15.9) in immigrants and 6.9% (95%CI: 5.6–8.5) in other
groups. Among the above study parameters considered
during meta-regression analysis, only study years were asso-
ciated with a decreasing HBV prevalence over time (Add-
itional file 3). The meta-regression plots for the mean age
group and study years were presented in Additional file 4.
Similarly, many studies in symptomatic liver disease pa-
tients reported HBsAg detection ranging from 9.9 to 35.8%
[44–51] with a median prevalence of 21.2% (IQR = 13.4–
33.6) (Table 2). The meta-analysis estimate among these pa-
tients also showed 20.0% (95%CI: 15.0–26.1) (Additional
file 5).
In some studies, along with HBsAg other HBV
markers; anti-hepatitis B surface antigen (anti-HBs),
anti-hepatitis B core antigen (anti-HBcAg) and hepatitis
e Ag (HBeAg) and anti-hepatitis e antigen (anti-HBeAg)
were also determined (Table 3). The peak prevalence
rate (82%) for any markers was reported among chronic
liver disease patients, whereas the lowest rate (42.2%)
was in the general population [52]. The anti-HBs anti-
body was recorded at 11.6% in HIV infected individuals
[53] and the highest rate (73.6%) was among healthcare
workers [25]. Similarly, the HBeAg prevalence rate
ranges from 0.6 to 44.0% (Table 3).
Epidemiology of HCV
Except a 3% prevalence rate of the time for Ethiopian im-
migrants to Israel in 1991 [54], the seroepidemiological sur-
vey of HCV in a community based studies showed 0.8 to
2% prevalence rate before the year 2000 [55, 56]. Over the
years 2000s, relatively lower and comparable prevalence
rates were documented from blood donors in north
Ethiopia (1.7%) in 2007 [57], Gondar (0.7%) in 2010 [17],
Jimma (0.2%) [16] and Bahir Dar (0.6%) in 2011 [13]
(Table 4). In contrast, unusually high HCV prevalence was
reported in blood donors from Gondar (5.8%) in 2008 [9]
and from Bahir Dar (13.3%) in 2007 [8]. A similar variation
was also reported, among other groups, such as VCTclients
[10–12], diabetic patients [58], antenatal care (ANC) [39]
Fig. 3 The meta-analysis and forest plot presentation of the HBsAg seroprevalence from 1983 to 2015. (Citations of studies used in the analysis from top to
bottom: [85, 59, 91, 89, 29, 87, 25, 87, 26, 90, 92, 93, 54, 16, 88, 95, 96, 27, 9, 35, 38, 39, 57, 42, 97, 17, 31, 33, 32, 62, 30, 10, 34, 63, 13, 43, 42, 62, 64, 67, 53, 65])
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and medical waste handlers [32] (Table 4). Likewise, the
magnitude of anti-HCV antibody from chronic liver disease
patients showed a variable prevalence rate over time with
high (37.8%) in 1995 [49] and low (2.7%) in 2014 [51]
(Table 4). For the HCV meta-analysis, 24 (75.0%) studies
were eligible and selected from the total of 32 studies (Add-
itional file 2). The Cohran’s Q (283.1) and I2 statistics
(91.9%, p < 0.001) showed heterogeneity among studies.
The pooled prevalence rate of anti-HCV antibody was 3.1%
(95%CI: 2.2–4.4) (Fig. 4). The subgroup meta-analysis
showed significant variations in the HCV prevalence among
the study parameters (Table 1).
Epidemiology of HAV, HDV and HEV
An early report of HAV antibody prevalence rates was 84
and 50% [46, 59], respectively among the general population
and children. In regard to HDV, available scientific reports
in the 1980s showed from 5.8 to 9.6% of anti-HDV antibody
prevalence rates among the general population [59, 60].
HEV was also reported 59% in acute pregnant women [61]
and 93% in acute patients and 3% in healthy controls [47].
Epidemiology of viral hepatitis among HIV infected
individuals
Cases-control studies of HBsAg among HIV infected in-
dividuals showed a record of 14% (vs. 4.3% in the con-
trol) in Shashemene (Southern Ethiopia) [62] and 5.4%
(vs. 3.9% in the controls) from the central Ethiopia in
Addis Ababa [42]. Studies which included HIV infected
individuals alone reported 2.3% HBsAg prevalence rate
in Woldiya [63] and 5.6% in Gondar [64] and 6.9% in
Hawassa [65] from the north, northwest and south part
of Ethiopia, respectively. Overall, for the last 10 years,
the median HBsAg seroprevalence among HIV infected
individuals was 6.0% (IQR = 3.0–6.0) with an increased
trend prevalence (X2 = 15.1, p < 0.001) when compared
to HIV negative controls. In the subgroup meta-analysis,
HBV prevalence in HIV co-infected individuals was 5.2%
(95% CI 3.7–7.4, p < 0.001) (Table 1).
Table 1 Subgroup meta-analysis of HBV and HCV prevalence estimation in Ethiopia
Study parameters Subgroup Studies included Prevalence %(95% CI) I2% P-value
HBV Study population Community based 7 8.0 (5.9–10.7) 96.1 <0.001
Blood donors 6 8.4 (5.4–12.7) 95.4 <0.001
HIV co-infected 7 5.2 (3.7–7.4) 75.9 <0.001
Immigrants to Israel 5 11.0 (7.5–15.9) 79.0 0.001
Other groupsa 17 6.9 (5.6–8.5) 87.3 <0.001
Mean age groupb 14–29 8 7.1 (5.6–8.9) 85.3 <0.001
30–45 9 6.7 (5.6–8.1) 39.6 <0.001
Study year 1980–1989 9 9.4 (8.2–10.7) 74.5 <0.001
1990–1999 8 10.7(7.3–15.4) 94.3 <0.001
2000–2009 9 6.3 (5.1–7.9) 76.6 <0.001
2010–2015 16 5.7 (4.9–6.6) 63.4 <0.001
Geographical zone Central Ethiopia 13 6.4 (5.3–7.6) 81.3 <0.001
Northwest Ethiopia 17 8.2 (6.2–10.8) 93.7 <0.001
Other regionsc 12 7.7 (6.5–9.1) 82.6 <0.001
HCV Study population General populationd 16 2.4 (1.6–3.6) 90.4 <0.001
HIV co-infected 8 5.5 (3.8–7.8) 81.8 <0.001
Mean age group 19–29 6 2.3 (0.9–5.8) 96.6 <0.001
30–39 9 3.7 (2.4–5.8) 84.4 <0.001
Study year 1990–1999 3 2.0 (1.5–2.7) 0.00 <0.001
2000–2009 6 2.9 (1.4–5.9) 94.2 <0.001
2010–2015 15 3.7 (2.5–5.4) 88.2 <0.001
Geographical zone Central Ethiopia 6 3.5(2.0–6.0) 89.0 <0.001
Northwest Ethiopia 10 2.8(1.6–4.7) 87.8 <0.001
Other regionse 8 3.4(1.7–6.5) 94.8 <0.001
aOther groups include: healthcare workers and medical waste handlers, out and inpatient department patients, street dwellers, pregnant women, diabetic
patients, HIV voluntary counseling and testing (VCT) centers clients and commercial sex workers. bIt considered for those studies which only reported mean age
cIncludes: Nationwide studies (n = 3), North (n = 1), North east (n = 2), South east (n = 5) and South west (n = 1). dIt includes: Community based studies, blood
donors, HIV co-infected and immigrants. eone, three, one, and three studies were from nationwide, north, northeast and southwest Ethiopia, respectively
Belyhun et al. BMC Infectious Diseases  (2016) 16:761 Page 6 of 14
The prevalence rate of HCV antibody in HIV infected
individuals was 4.5%, which was higher than HIV nega-
tive controls (0.8%) in Addis Ababa [55]. A study from
southern Ethiopia in Hawassa [11] showed a 10.5%
prevalence of HCV in HIV infected individuals com-
pared to 6.0% in the HIV negative control group. In this
report and another similar study in Addis Ababa [65],
HCV viraemia was reported 9.1 and 25.4%, respectively
from anti-HCV antibody positive individuals. Overall,
the HCV prevalence showed an increasing trend prevalence
(X2 = 18.7, p < 0.001) in HIV infected individuals than non-
infected counterparts with a median prevalence of 6.5%
(IQR = 4.2–9.9) [11, 12, 53, 55, 64, 66–69]. In the subgroup
meta-analysis, the prevalence of anti-HCV antibody in HIV
co-infected individuals was 5.5% (95% CI 3.8-7.8, p < 0.001),
respectively (Table 1 and Additional file 4). Unlike mean
Table 2 HBsAg prevalence of acute and chronic liver disease patients in different regions of Ethiopia from 1984 to 2013
Sampling
year




Patients’ characterization and evaluation systema References
1984 A.Ababa Prospective longitudinal 304 30(9.9) Patients with acute or chronic hepatitis, some with
malignant liver disease, mainly hepatocellular
carcinoma (HCC)
[45]
1989 A.Ababa Consecutive hospital patients 334 91(27.2) Based on clinical and histological diagnostic criteria;
patients with chronic hepatitis (n = 114), cirrhosis




Epidemic outbreak 423 54(12.8) Icteric patients hospitalized during HEV [47]
1992 A.Ababa Consecutive hospital patients 110 22(20.0) Consecutive acute hepatitis patients and 19
pregnant women who had HEV infection
[48]
1995 A.Ababa Consecutive hospital patients 238 65(27.3) Patients with chronic hepatitis (n = 14), cirrhotic
(n = 156) and HCC (n = 68)
[49]
2011 A.Ababa Prospective consecutive
hospital patients
120 43(35.8) Patients with chronic liver disease based on clinical
history, ultrasound, and impaired liver function tests.
[44]
2011 Gondar Retrospective 2684 386(14.4) Five year retrospective study on clinically suspected
hepatitis patients from different wards of Gondar
hospital
[50]
2013 Bale Robe Retrospective 358 80(22.3) All patients with chronic hepatitis [51]
aThe clinical diagnostic criteria for grouping patients as chronic liver disease patients were based on the presence of patient history of either clinical signs like
ascites, hepatomegaly, and splenomegaly with other clinical features including jaundice, palmar erythema, clubbing, edema, axillary and pubic hair loss, Spider
nevi, flapping tremors, drowsiness, confusion and coma. Ultrasound showing coarse hepatic texture, changes in liver size, increased portal vein diameter, and
splenomegaly. Impaired liver function tests, including raised level of alanine aminotransferase (ALT)
Table 3 Magnitude of HBV markers among different study populations in different regions of Ethiopia from 1983 to 2011
Other HBV markers References
Sampling
year
Study area Study groups Sampled
population








1983 Nationwide Gen. population,
children & ANC
attendants
396 36 (9.1) 221 (67.2)a - 19(55.9)d 15(44.0)g [85]
1984 Nationwide General population 500 31 (6.2) 152 (30.4) 16 (3.2) 10(32.3)e 8(25.8)e [52]
1987 A. Ababa Health workers 432 39 (9.02) 200 (46.3) 316 (73.1) - - [29]
1989 Nationwide General population 5265 569 (10.8) 61.4b 132 (2.5) 298(57.1)f 99(19.0)f [26]
1994 A.Ababa General population 4736 292 (6.2) 1796(40.7)c 1734 (36.6) - 71/279 (25.4) [27]
1995 A.Ababa Chronic liver disease
patients
238 65 (27.0) 131 (55.0) - - - [49]
1998 Immigrants to Israel Familial members 506 84 (16.6%) - - - 17/84(20.2) [95]
2007 A. Ababa HIV patients & VCT
clients
620 29 (4.7) - 277 (44.7) - 3/29(10.3) [42]
2010 Gamo HP Inpatients department
clients
556 26 (4.7) - 7 (1.4) - - [33]
2011 A.Ababa HIV patients 500 15(3.0) 58(11.6) - - 3(0.6) [53]
aANC-Antenatal Care. bOnly the percentage was presented from the origional study. HBeAg and anti-HBeAg percentages were calculated on the basis of
sample size of HBsAg positive individuals; e = 31, d = 34, f = 522 and g = 19. a = 329 and c = 4414 among HBsAg negatives
Belyhun et al. BMC Infectious Diseases  (2016) 16:761 Page 7 of 14
age, study year and geographical zones, the meta-regression
analysis showed that HIV co-infection was associated
with higher HCV prevalence rate (Additional files 3
and 4).
Discussion
This is the first detailed systematic review and meta-
analysis study of viral hepatitis in Ethiopia over a large
period of time. The findings clearly show the burden of
viral hepatitis in the country in general and endemicity
of HBV in particular. The findings were also consistent
with the estimate of 5–20% of most African countries
[70] and the WHO HBV endemic definition (5–7%
HBsAg prevalence) in the general population of a de-
fined geographical area [1]. Similarly, HBV markers
other than HBsAg ever reported in the country have
Table 4 Magnitude of HCV antibody prevalence among different study population in different regions of Ethiopia from 1988 to 2014
Study group Sampling year Study area Study population Anti-HCV Ab frequency (%) References
Community based 1993 A.Ababa & its outskirts 1580 32 (2.0) [56]
1994 A.Ababa 2663 29 (0.8) [55]
2002 Kemissie & Omo 5248 68 (1.3) [28]
Blood donors 1995 A.Ababa 500 7 (1.4) [49]
2003 North Ethiopia 600 10 (1.7) [57]
2004 Gondar 600 35 (5.8) [9]
2006 Bahirdar 324 43 (13.3) [8]
2007 Gondar 6361 35 (0.7) [17]
2008 Bahir Dar 2384 15 (0.6) [13]
2010 Jimma 6063 12 (0.2) [15]
Symptomatic liver disease patients 1988 North Ethiopia 139 20 (14.0) [47]
1992 A.Ababa 110 21 (19.0) [48]
1995 A.Ababa 238 90 (37.8) [49]
2011 A. Ababa 120 27 (22.5) [44]
2011 Gondar 2684 322 (12.0) [50]
2013 Bale Robe 220 6 (2.7) [51]
HIV infected individuals 1994 A. Ababa 165 8(4.8) [55]
2006 A. Ababa 734 50 (6.8) [66]
2008 Hawassa 400 42(10.5) [11]
2011 A. Ababa 500 18 (3.6) [53]
2011 Mekele 174 16(9.2) [12]
2012 D/ Tabour 395 5(1.3) [67]
2013 A.Ababa 387 25(6.5) [68]
2013 Gondar 400 22(5.5) [64]
2013 Bahirdar 269 59(21.9)a [100]
2014 Bahirdar 253 14(5.5) [69]
Othersb 2006 Gondar 480 6 (1.3) [39]
2006 A. Ababa 1220 21 (1.7) [66]
2008 Hawassa 400 24(6.0) [11]
2010 Jimma 304 30 (9.9) [58]
2010 Jimma 300 10 (3.3) [58]
2010 Gamo HP 556 1 (0.2) [33]
2011 Gondar 200 2 (1.0) [32]
2011 Mekele 126 2 (1.6) [12]
2012 D/ Markos 423 6 (1.4) [10]
aReported as 18.9% in the original work, but the 3.0% anti-HCV antibody reported as co-infected with HBsAg was summed up and became 21.9%
bIncludes antenatal care attendants, HIV voluntary counselling and testing (VCT) clients (HIV negative), VCT clients, diabetic patients, non-diabetic patients (controls
for diabetic patients), out and inpatient department clients, healthcare workers and medical waste handlers, and VCT clients
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been in agreement with data from most African coun-
tries and support the endemicity of HBV estimated from
the HBsAg prevalence.
HBV seroprevalence studies in blood donors were
merely geographical representative, which covered north,
northwest, southwest and central parts of Ethiopia.
However, the HBsAg prevalence in this group was a bit
higher (8.4%) than the community based studies (8.0%),
but in agreement with reports on blood donors of other
African countries [70–72]. Nevertheless, in Ethiopia,
studies in this group showed a marked variation even in
the same locality with exceptionally highest [8, 14] or
lowest [13, 15] prevalence rates over time. Apart from
geographical location and study time differences, the dis-
crepancies in this group in particular and other groups
in general could be due to methodological drawbacks
such as small sample size seen from southwest Ethiopia
[14] and ill-defined study design from northwest
Ethiopia [50]. For instance, the latter study failed to ex-
clude patients who were screened HBsAg for differential
diagnosis of other illness, but rather reported 14.4%
HBsAg prevalence by considering the subject as ‘clinic-
ally suspected viral hepatitis patients’. The other source
of the discrepancy might be due to the potential variabil-
ity in sensitivity and specificity of the commercially
available test kits used in each study, although the stud-
ies used in this review were based on an immunoassay
based screening kits with more or less similar principle
of antibody detection.
From early 1980s to the present time, more than
120,000 [73] Ethiopian Jews immigrated to Israel. Be-
cause of the low standards of socio-economic and
healthcare status of these migrants, they attracted the
focus of public health intervention and were screened
for infectious disease agents including hepatitis viruses
[74, 75]. The 11.0% HBsAg prevalence rate observed
were higher than the blood donors, the general popula-
tion and other groups. This could be due to the fact that
the immigrates were originally from rural Ethiopians
communities where risky traditional unsafe practices
(tattooing, ear piercing, tonsillectomy, circumcision, rit-
ual scars, traditional surgery, unsterilised shaving at the
barber shop, dental extraction at home, home delivery
by traditional birth attendants, unsafe abortion practices)
are commonly practiced. The finding in this group, how-
ever, could represent and reflect HBV prevalence in the
rural settings of Ethiopia since the majority of the stud-
ies concentrated in urban settings. Moreover, the preva-
lence observed in these immigrants also could indirectly
reflect the potential distribution dynamics of hepatitis
viruses to the less endemic parts of the world.
In Ethiopia, reports on HBsAg prevalence were also
common from groups such as pregnant women, diabetic
patients, street dwellers, HIV VCT clients and commer-
cial sex workers. The HBsAg prevalence was hyperen-
demic among healthcare professionals [29] and medical
waste handlers [30] in particular might be associated
with occupational risk exposures since they deal with all
Fig. 4 The meta-analysis and forest plot presentation of anti-HCV seroprevalence from 1993 to 2015. (Citations of studies used in the analysis from
top to bottom: [56, 54, 49, 55, 57, 28, 9, 39, 68, 58, 58, 11, 66, 12, 66, 11, 12, 53, 64, 10, 67, 32, 98, 99])
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sorts of the infected samples with no HBV vaccination,
which is the simplest protection and standard practice
elsewhere. A recent study showed that although know-
ledge about availability of HBV vaccine was 62% among
healthcare workers, fully vaccinated professionals were
only 5.4% [76]. Another study conducted on Ethiopian
surgeons showed that most of them were not vaccinated
because of negligence and lack of knowledge about the
recent introduction of the vaccine, despite their strong
belief HBV vaccine is useful [77]. This could explain the
reason that the relatively higher prevalence rate of
HBsAg and anti-HBS antibody level among healthcare
workers in Ethiopia since the exposure and subsequent
natural immune development could be expected rela-
tively higher in this group. As the result, to minimize at
least an occupational exposure of HBV infection for
such risky groups, an urgent need for the HBV vaccination
scheme, awareness creation and attitudinal health educa-
tion on the universal precaution and safety of blood born
infection transmissions are crucial in Ethiopia.
The disease burden caused by HBV and other forms of
hepatitis is undocumented in Ethiopia, although acute
viral hepatitis, chronic hepatitis, cirrhosis of the liver
and HCC accounted for significant hospital admissions
and mortality rate [78]. In late 1990s, the most common
tumour in medical units in Ethiopia was associated with
a 50% carrier rate of HBsAg [7, 78]. In line to this, the
overall HBsAg prevalence in the symptomatic liver dis-
ease patients estimated 20.0 and 21.2% from the meta-
analysis and systematic review analysis, respectively.
Regarding HCV, the prevalence rate in different time
zones was estimated in Ethiopia before as 1.9% [79],
1.3% [80] and 2.7% [81] as part of the HCV epidemio-
logical estimation in sub Saharan African countries.
However, the above estimates were limited in terms of
numbers of studies included, study time, study groups
and geographical representation of the studies available
throughout the country. For instance, the former two esti-
mates were made from four studies [9, 17, 28, 56] in which
two of them were from blood donors of the same study
area. However, in the current study, a comprehensive esti-
mate analysis was made from three groups independently
analysed as the general population (includes community
based, blood donors, healthcare workers, etc.), symptom-
atic liver disease patients and HIV infected individuals
representing a vast geographical area of the country and
time. The overall 3.1% pooled prevalence estimate and the
magnitude of anti-HCV antibody from 2.7 to 37.8% in
chronic liver disease patients [44, 49], therefore, might
show the true epidemiological picture and the real burden
of HCV in Ethiopia. This is also supported by the level of
HCV viraemia reported in 25.4% of HCV antibody positive
individuals [66]. The pooled prevalence in this study was
higher than the recent reports from neighbouring
countries of 0.3% in Djibouti, 0.9% in Somalia, and 1.0% in
Sudan [82] but in line with a 3.0% prevalence estimate of
most other African countries [79, 83]. The risk factors dis-
cussed for transmission of HBV in Ethiopia also might
play their own roles in the transmission of HCV, although
the degree of transmission potential varies for both
viruses.
Similarly, unlike HBV and HCV, prevalence studies of
HAV, HDV and HEV among the general population and
liver disease patients were very few in Ethiopia. The data
available so far [47, 60, 61, 84] showed a considerate
prevalence particularly for HAV and HEV infections.
These viruses are transmitted by the faecal-oral route
and many of the environmental and socio-economic fac-
tors foster the transmission routes. In Ethiopia, the ex-
posure to HAV at least once in every individual was
common and the prevalence rates range from eight to
99% in the general population [48, 85]. However, unlike
the blood born viral hepatitis, HAV and HEV do not
commonly exist in a chronic carrier state [84] and they
are very different in exposures/transmissions. In Africa,
HEV infection is widespread and is expected to be a
threat to numerous lives, especially for those pregnant
women and their foetuses [4]. A serological data from
Egypt showed that the seroprevalence of anti-HEV can
reach close to 100% in the general population [4]; similar
to anti-HAV prevalence in Ethiopia and elsewhere in Af-
rica [84, 86]. It was also reported that in many countries
like Sudan, Chad, Uganda, Kenya, Somalia and Ethiopia
a number of large HEV outbreaks occurred at different
times [4]. For instance, in Uganda alone, the mortality
rate among children younger than 2 years of age was 8%
[4]. Similarly, in Ethiopia, the HEV antibody seropreva-
lence observed in jaundice patients was 93% [48] but the
least from acute sporadic patients (33%) [48], pregnant
women (59%) and healthy adults (3%) [48]. According to
this report, in the early 1990s, HEV was a common
cause of acute sporadic viral hepatitis in Ethiopian pa-
tients. In particular, the occurrence during pregnancy
was associated with high maternal and foetal morbidity
and mortality [48]. Although there is no current study
available to compare, the late 1980s HDV reports ranged
from 5.8 to 9.6% could classify Ethiopia as one of an en-
demic country. The worldwide estimation also indicated
that 5% of HBsAg carriers were infected with HDV [5].
In Ethiopia, an old report showed that the distribution
of HBV markers was similar to anti-HDV positive and
anti-HDV negative individuals due to the relatively
young age of the population and/or hyperendemic con-
dition of the area [60].
Although an increasing pattern of viral hepatitis in
general is predictable from HIV infected individuals in
Ethiopia, unlike HCV (5.5%), the co-prevalence estimate
of HBV (5.2%) with HIV were lower than the estimate of
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other groups. Similarly, the meta-regression analysis
showed a decreasing pattern of overall HBsAg prevalence
rate over study year. The intensive prevention and control
measures done after the era of HIV pandemic might be re-
sponsible for HBV exposure reduction. Therefore, this
could might encourage a need for integrating HBV man-
agement to the HIV prevention and control programs in
Ethiopia. However, unlike HBV, the HCV seroprevalence
analysis in the HIV infected individuals was higher up to
two folds than HIV negative controls. Regarding the HAV,
HDV and/or HEV co-infections with HIV in Ethiopia,
there are no data available to compare with mono-
infection of each hepatitis virus.
Conclusion
Given the potential limitations arising from small sample
size study effects, inconsistency of the screening kits
used in the studies as well as study design, time and area
heterogeneity, the findings from the systematic review
and meta-analysis were in agreement with each other
and indicates all forms of viral hepatitis infection are
common in Ethiopia. In particular, HBV and HCV and/
or their respective co-infection with HIV are prevalent
and endemic. These could be taken as one of the na-
tion’s public health problems and potential healthcare
threats especially in compromising HIV management.
Recent studies on the magnitude of HAV, HDV and
HEV are lacking, hence, the need for further studies to
generate up-to-date data is recommended. Developing
viral hepatitis diagnosis algorithms, treatment schemes
and an enhanced HBV vaccination program for children
and risk groups in Ethiopia are strongly recommended.
The HBV/HCV co-prevalence with HIV supports the
need for preventive measures and screening of viral
hepatitis in Ethiopia and could be integrated into the
country’s existing HIV prevention and control programs.
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